Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models
GlobeNewswire
-- Preclinical data continues to demonstrate PAS-004’s potentially superior properties as compared to FDA approved MEK..